Leerink Swann upgraded Illumina Inc (NDAQ:ILMN) from Mkt Perform to Outperform in a report released today.
- Updated: March 20, 2017
Leerink Swann has upgraded Illumina Inc (NDAQ:ILMN) from Mkt Perform to Outperform in a report released on 3/20/2017.
Just yesterday Illumina Inc (NDAQ:ILMN) traded 0.60% higher at $163.47. Illumina Inc’s 50-day moving average is $163.67 and its 200-day moving average is $152.69. The last stock price is up 5.06% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 1,917,751 shares of ILMN traded hands, up from an average trading volume of 1,098,660
Recent Performance Chart
Illumina Inc has 52 week low of $119.37 and a 52 week high of $186.88 with a PE ratio of 52.25 and has a market capitalization of $0.
In addition to Leerink Swann reporting its stock price target, a total of 19 brokerages have issued a ratings update on the company. The average stock price target is $154.53 with 4 brokerages rating the stock a strong buy, 4 brokerages rating the stock a buy, 15 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Illumina Inc (NDAQ:ILMN)
Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.